Skip to main content
OpenTrials
Completed

NCT Number: NCT01291173

Forced-dose Titration of SPD489 in Adults With Binge Eating Disorder

To evaluate the efficacy of SPD489 compared to placebo in the treatment of moderate to severe binge eating disorder as measured by the number of binge days per week

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Clinical Study Centers, LLC, Little Rock, Arkansas, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion

  • Subject meets the following Diagnostic and Statistical Manual of Mental Disorders Fourth Edition - Text Revision (DSM-IV-TR) criteria for a diagnosis of binge eating disorder (BED).
  • Binge eating disorder is of at least moderate severity in which subjects report at least 3 binge eating days per week.
  • Subject has a body mass index (BMI) of >24 and <46.

Exclusion

  • Subject has concurrent symptoms of bulimia nervosa or anorexia nervosa.
  • Subject is considered a suicide risk or risk to harm others.

Treatment and study plan

lisdexamfetamine dimesylate (SPD489)

Drug

SPD489-30mg capsules taken once daily for up to 11 weeks

Other names: LDX, Vyvanse

Placebo

Drug

Placebo capsule taken once daily for up to 11 weeks

Primary outcomes

  1. Change From Baseline in Log Transformed Binge Days Per Week at Week 11

    Time frame: Baseline and week 11

    Binge day is defined as a day during which at least 1 binge episode occurs.

Secondary outcomes

  1. Change From Baseline in the Number of Binge Episodes Per Week at Up to 11 Weeks

    Time frame: Baseline and up to 11 weeks

    The number of binge episodes per week as assessed by clinical interview based on subject diary.

  2. 1-Week Binge Response, Last Observation Carried Forward (LOCF)

    Time frame: Last 7 days on study

    The 1-week binge response was defined as either a 1-week remission (a 100% reduction of binge episodes from baseline [ie, a cessation of binge eating behavior]), or a marked response (75 to <100% reduction in binge episodes from baseline), or a moderate response (50 to <75% reduction in binge episodes from baseline), or a negative/minimal response (<50% reduction in binge episodes from baseline). The 1-week response was determined at the end of the study utilizing a LOCF approach.

  3. 4-Week Binge Response

    Time frame: Last 28 days on study

    Subjects are free from binge episodes for 4 weeks.

  4. Percent of Participants With Clinical Global Impression - Severity of Illness (CGI-S) at Baseline

    Time frame: Baseline

    CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)

  5. Percent of Participants With Clinical Global Impression - Severity of Illness (CGI-S) at Up to 11 Weeks

    Time frame: up to 11 weeks

    CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)

  6. Percentage of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) at Up to 11 Weeks

    Time frame: Up to 11 weeks

    Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.

  7. Change From Baseline in Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating (YBOCS-BE) Total Score at Week 11

    Time frame: Baseline and week 11

    The YBOCS-BE measures the obsession of binge-eating thoughts and compulsiveness of binge-eating behaviors. The scale is a clinician-rated, 10-item scale, each item rated from 0 (no symptoms) to 4 (extreme symptoms). Total scores range from 0 to 40. A score of 0-7 is sub-clinical; 8-15 is mild; 16-23 is moderate; 24-31 is severe; and 32-40 is extreme.

  8. Change From Baseline in Montgomery-Ǻsberg Depression Rating Scale (MADRS) Score at Week 11

    Time frame: Baseline and week 11

    MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression.

  9. Change From Baseline in Hamilton Anxiety Rating Scale (HAM-A) Score at Week 11

    Time frame: Baseline and week 11

    The HAM-A is a rating scale developed to quantify the severity of anxiety symptomatology. It consists of 14 items, each defined by a series of symptoms. Each item is rated on a 5-point scale, ranging from 0 (not present) to 4 (severe) with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity, and 25-30 moderate to severe, and 31-56 severe anxiety.

  10. Change From Baseline in Eating Inventory Score at Week 11

    Time frame: Baseline and week 11

    The Eating Inventory also known as the Three-Factor Eating Questionnaire is a 51-item self-reported questionnaire intended to assess 3 dimensions of eating behavior: cognitive restraint of eating, disinhibition, and hunger. Cognitive restraint of eating consists of 20 items, disinhibition consists of 16 items, and hunger consists of 15 items. Each item scores either 0 or 1 point for a total score of 0-20 for cognitive restraint of eating, 0-16 for disinhibition, and 0-15 for hunger. A higher score is better for cognitive restraint of eating and lower scores are better for disinhibition and hunger.

  11. Change From Baseline in Binge Eating Scale (BES) Score at Week 11

    Time frame: Baseline and week 11

    The BES is a 16-item self-reported questionnaire that is designed to assess behavioral, affective, and attitudinal components of the subjective experience of binge eating. The items are summed, with possible scores ranging from 0 to 46. A score of 27 or higher indicates severe binge-eating problems, and a score of 17 or lower designates no binge-eating problems.

  12. Change From Baseline in Barratt Impulsiveness Scale (BIS-11) Total Score at Week 11

    Time frame: Baseline and week 11

    The BIS-11 is a self-reported 30-item questionnaire that measures impulsiveness using a 4-point Likert scale (rarely/never = 1, occasionally = 2, often = 3, almost always/always = 4). A Total Impulsivity score is calculated by summing the scores for each item. Possible scores range from 30 - 120. Higher scores indicate increased impulsiveness.

  13. Change From Baseline in Short Form-12 Health Survey (SF-12) Score at Week 11

    Time frame: Baseline and week 11

    The SF-12 is a 12-item self-report questionnaire that is a subset of the SF-36 Health Survey. The survey captures physical and mental health. There are 8 subscales. Four of the subscales has one-item each; the other 4 have two-items each. For each subscale, a mean value was first computed and transformed to a position on a scale ranging from 0-100 (Z-transformation). The aggregate total scores are then transformed into a mean value ranging from 0 (lowest level of health) to 100 (highest level of health).

Sponsors and collaborators

Lead sponsor

Shire

Industry

Registry information

Official study title

A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Forced-dose Titration Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Binge Eating Disorder

Acronym: BED

Important dates

Study start
2011
Primary completion
2012
Study completion
2012
First posted
Feb 8, 2011
Registry last updated
Jun 10, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.